ADCT vs LLY · rev $40.1M vs P/E 39, rev $22.97B
ADC Therapeutics SA (ADCT) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
ADCT currently screens at market cap $141.2M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the ADCT and LLY stock pages for the full models.
Not investment advice.